Research and Markets (http://www.researchandmarkets.com/research/rw282z/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Treatment Resistant Depression Overview
  4. Therapeutics Development
  5. Pipeline Products for Treatment Resistant Depression - Overview
  6. Pipeline Products for Treatment Resistant Depression - Comparative Analysis
  7. Treatment Resistant Depression - Therapeutics under Development by Companies
  8. Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes
  9. Treatment Resistant Depression - Pipeline Products Glance
  10. Late Stage Products
  11. Clinical Stage Products
  12. Early Stage Products
  13. Treatment Resistant Depression - Products under Development by Companies
  14. Treatment Resistant Depression - Products under Investigation by Universities/Institutes
  15. Treatment Resistant Depression - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/rw282z/treatment